---
title: "Inaxaplin (VX-147) in APOL1-mediated kidney disease: Generic, brand name and therapeutic class of product"
description: "Formulary evidence on Inaxaplin (VX-147) in APOL1-mediated kidney disease: Generic, brand name and therapeutic class of product. Topics: Generic name, chemical name, and identifiers; Development codes: VX-147 and IXP; Manufacturer: Vertex Pharmaceuticals; Therapeutic class: oral small molecule inhibitor of APOL1. 4 evidence topics quoted from 10 sources."
canonical: "https://www.evicenter.com/drugs/inaxaplin--apol1-mediated-kidney-disease/product-information-and-disease-description/generic-brand-name-and-therapeutic-class-of-product"
published: "2026-11-15T23:17:22-05:00"
modified: "2026-11-17T19:46:25-05:00"
---

# Inaxaplin (VX-147) in APOL1-mediated kidney disease: Generic, brand name and therapeutic class of product

<a id="heading-2.1.2.1"></a>

## 2.1.2.1 Generic, Brand Name and Therapeutic Class of Product

<a id="topic-2.1.2.1-1"></a>

### Generic name, chemical name, and identifiers

| Field | Quoted record |
| --- | --- |
| International nonproprietary name (Latin) | “inaxaplinum” |
| International nonproprietary name (English) | “inaxaplin” |
| Chemical name | “3-[5,7-difluoro-2-(4-fluorophenyl)-1H-indol-3-yl]-N- [(3S,4R)-4-hydroxy-2-oxopyrrolidin-3-yl]propanamide” |
| Functional description | “apolipoprotein L1 (APOL1) function inhibitor” |
| Molecular formula | “C21H18F3N3O3” |
| CAS registry number | “2446816-88-0” |
| INN list | “Proposed INN: List 125” |

Source: [WHO Drug Information (2021)](https://cdn.who.int/media/docs/default-source/international-nonproprietary-names-%28inn%29/pl125.pdf)

<a id="topic-2.1.2.1-2"></a>

### Development codes: VX-147 and IXP

> “the U.S. Food and Drug Administration (FDA) has granted inaxaplin (VX-147) Breakthrough Therapy Designation for APOL1-mediated focal segmental glomerulosclerosis (FSGS)”

Source: [Vertex Pharmaceuticals press release, Breakthrough Therapy and PRIME designations (2022)](https://news.vrtx.com/news-releases/news-release-details/vertex-announces-inaxaplin-vx-147-granted-breakthrough-therapy)

> “Other Names: IXP VX-147”

Source: [ClinicalTrials.gov NCT06794996](https://clinicaltrials.gov/study/NCT06794996)

<a id="topic-2.1.2.1-3"></a>

### Brand name

No evidence found.

<a id="topic-2.1.2.1-4"></a>

### Manufacturer: Vertex Pharmaceuticals

> “Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced positive results from the Phase 2b AMPLIFIED study of inaxaplin in people with APOL1-mediated kidney disease (AMKD) and modest proteinuria and in people with AMKD and type 2 diabetes.”

Source: [Vertex Pharmaceuticals press release, AMPLIFIED results (2026)](https://news.vrtx.com/news-releases/news-release-details/vertex-announces-positive-results-phase-2b-amplified-study)

> “We are developing inaxaplin, a small molecule inhibitor of APOL1 as a potential first-in-class treatment for APOL1-mediated kidney disease”

Source: [Vertex Pharmaceuticals Form 10-K (2026)](https://www.sec.gov/Archives/edgar/data/875320/000087532026000056/vrtx-20251231.htm)

| Field | Quoted record |
| --- | --- |
| Sponsor | “Vertex Pharmaceuticals Inc.” |
| Marketing authorisation holder of the investigational product | “VERTEX PHARMACEUTICALS, INCORPORATED” |

Source: [CTIS.eu 2024-515633-15-00](https://ctis.eu/trial/2024-515633-15-00)

<a id="topic-2.1.2.1-5"></a>

### Therapeutic class: oral small molecule inhibitor of APOL1

> “Vertex has discovered and advanced multiple oral, small molecule inhibitors of APOL1 function, including inaxaplin, pioneering a new class of medicines that targets the underlying cause of this genetic kidney disease.”

Source: [Vertex Pharmaceuticals third quarter 2026 results (2026)](https://www.sec.gov/Archives/edgar/data/875320/000087532026000287/ex-991_q32026.htm)

> “Inaxaplin is a first-in-class, investigational small molecule inhibitor of APOL1 aimed at addressing the underlying cause of AMKD.”

Source: [Vertex Pharmaceuticals press release, kidney portfolio advancements (2025)](https://news.vrtx.com/news-releases/news-release-details/vertex-announces-key-advancements-across-kidney-portfolio)

> “Vertex is developing inaxaplin, a potential first-in-class, investigational, oral small molecule inhibitor of APOL1, with the goal of targeting the underlying cause of AMKD.”

Source: [Vertex Pharmaceuticals press release, ASN Kidney Week (2024)](https://news.vrtx.com/news-releases/news-release-details/vertex-provides-updates-multiple-kidney-programs-american)

> “This medicine belongs to the class of apolipoprotein L1 inhibitors.”
> “Inaxaplin is an inhibitor of the apolipoprotein L1 protein (APOL1).”

Source: [EMA orphan designation EU/3/22/2697 (2022)](https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-22-2697)

## Related pages
- [Inaxaplin (VX-147): APOL1-mediated kidney disease](https://www.evicenter.com/drugs/inaxaplin--apol1-mediated-kidney-disease) · [Markdown](https://www.evicenter.com/drugs/inaxaplin--apol1-mediated-kidney-disease.md)
- [Inaxaplin (VX-147) in APOL1-mediated kidney disease: Terms and abbreviations](https://www.evicenter.com/drugs/inaxaplin--apol1-mediated-kidney-disease/terms-and-abbreviations) · [Markdown](https://www.evicenter.com/drugs/inaxaplin--apol1-mediated-kidney-disease/terms-and-abbreviations.md)
- [Inaxaplin (VX-147): APOL1-mediated kidney disease](https://www.evicenter.com/drugs/inaxaplin--apol1-mediated-kidney-disease/executive-summary) · [Markdown](https://www.evicenter.com/drugs/inaxaplin--apol1-mediated-kidney-disease/executive-summary.md)
- [Inaxaplin (VX-147) in APOL1-mediated kidney disease: Product information and disease description](https://www.evicenter.com/drugs/inaxaplin--apol1-mediated-kidney-disease/product-information-and-disease-description) · [Markdown](https://www.evicenter.com/drugs/inaxaplin--apol1-mediated-kidney-disease/product-information-and-disease-description.md)
- [Inaxaplin (VX-147) in APOL1-mediated kidney disease: Clinical evidence](https://www.evicenter.com/drugs/inaxaplin--apol1-mediated-kidney-disease/clinical-evidence) · [Markdown](https://www.evicenter.com/drugs/inaxaplin--apol1-mediated-kidney-disease/clinical-evidence.md)
- [Inaxaplin (VX-147) in APOL1-mediated kidney disease: Economic information and modeling report](https://www.evicenter.com/drugs/inaxaplin--apol1-mediated-kidney-disease/economics) · [Markdown](https://www.evicenter.com/drugs/inaxaplin--apol1-mediated-kidney-disease/economics.md)
- [Inaxaplin (VX-147) in APOL1-mediated kidney disease: References](https://www.evicenter.com/drugs/inaxaplin--apol1-mediated-kidney-disease/references) · [Markdown](https://www.evicenter.com/drugs/inaxaplin--apol1-mediated-kidney-disease/references.md)
